Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seroquel XR in elderly patients with Generalised Anxiety Disorder
NCT00389064Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2006
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of quetiapine in generalized anxiety disorder (GAD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Hamilton Rating Scale for Anxiety at 9 weeks. Started Sep 2006; status: completed.
02
Drugs
quetiapine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00389064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00389064.